Bplete Limited takes 100% stake in Perfect Balance Bio Limited
Published
Bplete Limited entered the register with a 100% holding in the biotech therapeutics developer, spanning Ordinary, B Ordinary and Series A shares.
Medicxi III LP exited its 76.1% Series A holding.
Medicxi Co-Invest III LP exited its 1.3% Series A holding.
Rxcelerate Limited exited its 1.3% B Ordinary holding.
The unchanged total indicates a transfer-only reorganisation, and the filing does not name recipients. The changes span a multi-year period, filed on 21 September 2026, covering 16 September 2021 to 16 September 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Exited | MEDICXI III LP | 4,719,681 | — | SERIES A 4,719,681 |
| Exited | MEDICXI CO-INVEST III LP | 80,319 | — | SERIES A 80,319 |
| Exited | RXCELERATE LIMITED | 80,000 | — | B ORDINARY 80,000 |
| New shareholder | BPLETE LIMITED | 6,200,000 | — | SERIES A 4,800,000 ORDINARY 1,000,000 B ORDINARY 400,000 |
Current shareholders (1)
| Shareholder | Total shares | Share classes |
|---|---|---|
| BPLETE LIMITED | 6,200,000 | B ORDINARY 400,000 ORDINARY 1,000,000 SERIES A 4,800,000 |
Similar companies
Companies with the most similar business descriptions.
More rounds like this
Contact the editorial team at editorial@fundingspotter.com